Podocyte injury pathway

The term "Podocyte injury pathway" does not refer to a single molecular target or receptor but rather encompasses multiple cellular and molecular mechanisms that lead to the dysfunction or loss of podocytes, which are specialized cells critical for maintaining the glomerular filtration barrier in the kidney. Injury to these cells is central to the pathogenesis of many proteinuric kidney diseases such as minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and diabetic kidney disease. Key mechanistic themes include: - Activation of innate immune pathways such as cGAS-STING leading to apoptosis/autophagy-mediated death. - Release of nuclear proteins like HMGB1 that interact with receptors including RAGE and TLR4 on podocytes, promoting apoptosis and EMT. - Upregulation of B7.1/CD80 on injured podocytes driving abnormal migration through β1 integrin inactivation; this can be therapeutically targeted by abatacept. - Disruption of actin cytoskeleton integrity resulting in foot process effacement ("podocytopathy"). - Mitochondrial dysfunction involving PGC‑1α downregulation leading to impaired energy metabolism and increased oxidative stress. - Endoplasmic reticulum stress responses contributing further cell death. Therapeutic strategies focus on modulating these upstream signals using biologics like rituximab/abatacept or small molecules targeting specific kinases/channels implicated in cytoskeletal regulation or inflammatory signaling. However, there is no discrete "Podocyte injury pathway" molecule—rather it is a conceptual grouping for several interrelated pathogenic processes affecting this cell type[1][2][3][4]. Because "Podocyte injury pathway" is not a canonical name for any one therapeutic target but instead refers broadly to multiple mechanisms/pathways involved in podocytopathies—and thus cannot be classified as an individual druggable entity—the entry should be marked as incorrect for structured drug-target databases.

Other names

Podocyte injury signalingPathways of podocyte damagePodocytopathy pathways

B cell depletion via anti-CD20 antibodies to reduce immune-mediated podocyte damage; Inhibition of T-cell co-stimulatory molecule CD80/B7.1 to prevent abnormal podocyte migration and effacement.